Healthcare -
Biotechnology - NASDAQ - US
$ 0.9039
10.1 %
$ 58.1 M
Market Cap
-0.56
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart INZY
FINANCIALS
Balance Sheet
Inozyme Pharma, Inc.
| Current Assets | 121 M |
| Cash & Short-Term Investments | 113 M |
| Receivables | 0 |
| Other Current Assets | 7.59 M |
| Non-Current Assets | 2.51 M |
| Long-Term Investments | 0 |
| PP&E | 1.35 M |
| Other Non-Current Assets | 1.16 M |
| Current Liabilities | 33.9 M |
| Accounts Payable | 2.53 M |
| Short-Term Debt | 15.4 M |
| Other Current Liabilities | 16 M |
| Non-Current Liabilities | 31.5 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 31.5 M |
EFFICIENCY
Earnings Waterfall
Inozyme Pharma, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 104 M |
| Operating Income | -104 M |
| Other Expenses | -2.01 M |
| Net Income | -102 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Inozyme Pharma, Inc.
| Net Income | -102 M |
| Depreciation & Amortization | 742 K |
| Capital Expenditures | -62 K |
| Stock-Based Compensation | 7.94 M |
| Change in Working Capital | 4.71 M |
| Others | 66 K |
| Free Cash Flow | -92 M |
Wall Street Analysts Price Targets
Inozyme Pharma, Inc.
Wall Street analysts predict an average 1-year price target for INZY of $14.8 , with forecasts ranging from
a
low of
$14 to a high of $16 .
INZY Lowest Price Target
Wall Street Target
14 USD
1448.84%
INZY Average Price Target
Wall Street Target
14.8 USD
1537.35%
INZY Highest Price Target
Wall Street Target
16 USD
1670.11%
4. DIVIDEND
ANALYSIS
INZY does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Inozyme Pharma, Inc.
Sold
0-3 MONTHS
7.85 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, from 2:15-2:55pm ET.
globenewswire.com
- 2 weeks ago
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support operations into the first quarter of 2026 - - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; topline data expected in first quarter of 2026 - - Positive interim results from ENERGY 1 trial and Expanded Access Program evaluating INZ-701 in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease - BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financial results for the full year ended December 31, 2024, and provided recent business highlights. "2024 marked a transformative year for Inozyme as we achieved critical milestones in our ENPP1 Deficiency program that enabled us to complete enrollment in our pivotal ENERGY 3 trial and announce promising interim data in infants and young children with ENPP1 Deficiency in January 2025," said Douglas A.
globenewswire.com
- 1 month ago
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, from 1:10-1:40pm ET.
globenewswire.com
- 1 month ago
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer, will present recently announced data from the company's Expanded Access Program (EAP) evaluating INZ-701 in infants and children with ENPP1 Deficiency at the CHOP Cardiology Annual Meeting, held February 19-23, 2025, in Orlando, Florida.
globenewswire.com
- 1 month ago
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.
globenewswire.com
- 4 months ago
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks
Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
- 5 months ago
Inozyme Pharma to Present at Upcoming Investor Conferences
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the following investor conferences:
globenewswire.com
- 5 months ago
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 –
globenewswire.com
- 5 months ago
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD -
globenewswire.com
- 5 months ago
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that interim data from the Company's ongoing Phase 1 SEAPORT 1 of INZ-701 in patients with end-stage kidney disease (ESKD) receiving hemodialysis will be presented during a poster session at the American Society of Nephrology (ASN) Kidney Week 2024, which is being held October 24-27, 2024, in San Diego.
globenewswire.com
- 5 months ago
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings to Inozyme over 20 years of commercial expertise within the biopharma industry.
globenewswire.com
- 6 months ago
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
Stifel initiated coverage on Inozyme Pharma Inc. INZY, saying, “This under-the-radar stock could be worth a look ahead of it.”
benzinga.com
- 7 months ago
8. Profile
Summary
Inozyme Pharma, Inc. INZY
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 58.1 M
Dividend Yield
0.00%
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Contact
321 Summer Street, Boston, MA, 02210
https://www.inozyme.com
IPO
Date
July 24, 2020
Employees
67
Officers
Dr. Douglas A. Treco Ph.D.
Chief Executive Officer & Chairman
Mr. Stephen J. Di Palma M.B.A.
Consultant
Dr. Soojin Kim Ph.D.
Senior Vice President & Chief Technical Operations Officer
Mr. Stefan Riley
Director of Investor Relations
Dr. Matthew Winton Ph.D.
Senior Vice President & Chief Operating Officer
Ms. Gayle Gironda
Senior Vice President & Chief People Officer
Dr. Demetrios Braddock M.D., Ph.D.
Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
Dr. Yves Sabbagh Ph.D.
Senior Vice President, Chief Scientific Officer & Chair of the Scientific Advisory Board
Mr. Axel Bolte M.B.A., M.Sc.
Co-Founder, Senior Advisor & Director
Mr. Sanjay S. Subramanian M.B.A., M.S.
Senior Vice President, Chief Financial Officer, Principal Accounting Officer & Corporate Secretary